FDA PMA
FDA Class 2
Approved
🇺🇸 United States
Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
PMA: P190011
·
Supplement: S001
·
Decision Apr 8, 2020
Classifications
1
FEI Numbers
24
Registration Numbers
24
Basic Information
- Device Name
- Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
- Trade Name
- LIAISON XL MUREX HCV Ab
- PMA Number
- P190011
- Supplement Number
- S001
- Device Class
- FDA Class 2
- Product Code
- MZO
- Generic Name
- Assay, enzyme linked immunosorbent, hepatitis c virus
- Medical Specialty
- Unknown
- Advisory Committee
- Microbiology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- April 8, 2020
- Date Received
- February 13, 2020
- Supplement Type
- Real-Time Process
- Supplement Reason
- Change Design/Components/Specifications/Material
- Expedited Review
- N
Advisory Committee Statement
Approval for System software update from software version 4.2.1.1 to software version 4.2.2.2 on the LIAISON® XL analyzer.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| MZO | Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus | FDA class 2 | Unknown |